USAP, FTC Reach Settlement in Landmark Texas Antitrust Case

DALLAS, TX – April 23, 2026 – U.S. Anesthesia Partners (USAP), one of the nation’s largest anesthesia providers, has reached an agreement in principle with the Federal Trade Commission (FTC) to resolve a high-profile antitrust lawsuit that accused the company of orchestrating a scheme to monopolize the market in Texas. The two parties have filed a joint request with the court to pause the case, allowing them to finalize the details of a settlement that could have far-reaching implications for healthcare consolidation and private equity investment across the country.

The agreement brings a potential end to a legal battle that began in September 2023, when the FTC alleged USAP engaged in a decade-long campaign of anti-competitive practices that systematically eliminated competition and drove up anesthesia prices, costing Texans tens of millions of dollars annually. While the specific terms of the settlement remain confidential pending finalization, the resolution marks a significant moment in the federal government's intensified scrutiny of healthcare mergers.

A Strategic End to a High-Stakes Battle

In a statement released today, USAP framed the decision as a pragmatic move to avoid a protracted and costly legal fight. The company emphasized that resolving the case is in the best interest of its patients, clinicians, and hospital partners, allowing it to move past the distraction and uncertainty of the litigation.

"There are uncertainties in any legal proceeding and this exceptionally prolonged litigation has required enormous time, energy, and financial commitments," said USAP Physician and Board Chairman Scott Holliday, DO, MBA. "In considering the best interests of our patients, clinicians, and hospital partnerships, we felt it was important to resolve this now so that USAP can remain laser focused on providing high-quality anesthesia services to our communities."

Crucially, the company noted that the final settlement will be made without any admission of fault by USAP. This clause allows the organization to end the legal challenge without formally conceding to the FTC's allegations. The agreement is still subject to several conditions and requires final approval from both the FTC commissioners and the U.S. District Court for the Southern District of Texas. The FTC has stated that if a final agreement is not executed, it is prepared to resume litigation.

The Anatomy of an Antitrust Challenge

The FTC's original complaint painted a detailed picture of what it called a multi-pronged strategy to dominate the Texas anesthesia market. The agency’s lawsuit was notable for targeting not just a single merger, but a series of acquisitions known as a "roll-up" strategy, which it claimed was designed and executed by USAP and its private equity founder, Welsh, Carson, Anderson & Stowe (WCAS), since 2012.

According to the complaint, USAP systematically acquired nearly every large, independent anesthesiology practice across major Texas metropolitan areas, including Houston, Dallas, and Austin. The FTC argued that this series of acquisitions, which gave USAP market shares ranging from 44% to 70% in key areas, effectively created a monopoly that gave the company overwhelming leverage in negotiations with insurance payors.

Beyond the acquisitions, the FTC also alleged that USAP engaged in price-setting arrangements with remaining independent anesthesia groups, using its higher negotiated rates to bill for their services. Furthermore, the agency claimed USAP struck a market allocation deal to sideline a potential competitor, ensuring it would not encroach on its territory. This combination of tactics, the FTC argued, violated federal antitrust laws and directly harmed Texas consumers through inflated healthcare costs.

However, the case saw a significant development in May 2024 when a federal judge dismissed the private equity firm, WCAS, from the lawsuit. The court ruled that WCAS, as a minority, non-controlling investor in USAP, could not be held liable for the company's alleged anti-competitive actions. This ruling was seen as a key clarification on the limits of liability for private equity investors in the portfolio companies they back.

A New Playbook for Healthcare Consolidation

This settlement is widely viewed as a significant victory for the FTC and its current leadership, which has made challenging healthcare consolidation a top priority. The case against USAP was a cornerstone of the agency's strategy to combat so-called "stealth consolidation" through serial acquisitions, a tactic regulators believe has flown under the radar for too long.

Under Chair Lina Khan, the FTC has signaled it will aggressively use its authority to scrutinize and challenge roll-up schemes, particularly those backed by private equity, which the agency contends often prioritize profits over competition and patient welfare. This settlement, regardless of its specific terms, sends a powerful message to other large physician groups and investors that the regulatory environment has fundamentally changed.

"This is the FTC drawing a line in the sand," commented one antitrust legal analyst who spoke on the condition of anonymity. "For years, a strategy of buying up small and mid-sized competitors one by one was seen as a viable way to build market power without triggering a major antitrust review. This case, and its resolution, signals that the agency is now connecting the dots and will challenge the entire pattern of conduct, not just individual deals."

The FTC has stated its goal for the settlement is to "restore a competitive market structure" in Texas. This suggests the final terms could include structural or behavioral remedies, such as prohibitions on future acquisitions in the state or other measures designed to unwind USAP's market concentration. Such conditions could serve as a template for future enforcement actions in other medical specialties and geographic regions.

The Ripple Effect on Patients and Providers

Ultimately, the impact of the settlement will be measured by its effect on the ground—for patients requiring surgery, hospitals managing operating rooms, and independent clinicians. The central premise of the FTC's lawsuit was that market dominance led to artificially high prices. If the settlement successfully fosters more competition, it could theoretically lead to lower costs for anesthesia services, which could translate into reduced insurance premiums and out-of-pocket expenses for patients.

Smaller, independent anesthesia practices in Texas may see the resolution as a positive development, potentially leveling a playing field they felt was tilted in favor of a dominant player. For hospital systems, the end of the litigation provides certainty in their relationship with a major service provider. However, they will be watching closely to see how any new market dynamics affect staffing, service reliability, and contract negotiations.

While USAP can now refocus its resources on its clinical operations, it will do so under a microscope. The healthcare industry will be closely observing how the company adapts its growth strategy in a post-settlement environment and what constraints, if any, are placed upon it. For now, the entire healthcare industry watches Texas, waiting to see how the final terms of this landmark settlement will reshape the landscape for physicians, patients, and investors alike.